glp 1 help with perimenopause GLP-1 Medications & Perimenopause: or Harm? Microdosing GLP-1 for Hormonal Weight

The genetic basis of AS leads to structural and functional disruptions of the glomerular basement membrane (GBM), driving early-onset fibrosis and inflammation

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

(PubMed) Luo T, Li J, Li L, et al

Monitor safety and risks proactively : The Veterans Affair study 1 found GLP-1 use was associated with an increased risk of 19 conditions, mainly affecting the digestive and musculoskeletal system

Now, I'm not afraid to make mistakes or be judged